Bowen Yi

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence et al. · Journal of Clinical Oncology · 2011 · 122 citations

Medicine, Oncology, Pharmacology +17

Paeoniflorin Promotes Angiogenesis in A Vascular Insufficiency Model of Zebrafish in vivo and in Human Umbilical Vein Endothelial Cells in vitro

Qiqi Xin, Binrui Yang, Hefeng Zhou et al. · Chinese Journal of Integrative Medicine · 2016 · 22 citations

Life Sciences, Pharmacology, Physiology +8

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy

Gang Li, Bowen Yi, Jingtong Liu et al. · Frontiers in Pharmacology · 2021 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment

Xu Lifang, Shuang Yu, Huining Liu et al. · European Journal of Clinical Pharmacology · 2022 · 15 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment

Zhongjian Wang, Wei Liu, Xueyan Li et al. · Regulatory Toxicology and Pharmacology · 2022 · 11 citations

Pharmacy, Pharmacokinetics, Pharmacology +16